Controlled release formulations exhibiting an ascending rate of release

Details for Australian Patent Application No. 2004275835 (hide)

Owner Alza Corporation

Inventors Edgren, David; Cruz, Evangeline; Ruhlmann, Gregory

Agent Shelston IP

Pub. Number AU-B-2004275835

PCT Pub. Number WO2005/030182

Priority 60/506,195 26.09.03 US; 60/570,981 14.05.04 US

Filing date 24 September 2004

Wipo publication date 7 April 2005

Acceptance publication date 23 June 2011

International Classifications

A61K 9/00 (2006.01) Medicinal preparations characterised by special physical form

A61K 9/24 (2006.01) Medicinal preparations characterised by special physical form - Layered or laminated unitary dosage forms

A61K 9/52 (2006.01) Medicinal preparations characterised by special physical form - Sustained or differential release type

A61K 31/00 (2006.01)

A61K 31/165 (2006.01) - having aromatic rings, e.g. colchicine, atenolol, progabide

A61K 31/485 (2006.01) - Morphinan derivatives, e.g. morphine, codeine

A61K 9/20 (2006.01) Medicinal preparations characterised by special physical form - Pills, lozenges or tablets

A61K 9/28 (2006.01) Medicinal preparations characterised by special physical form - Dragees

Event Publications

13 April 2006 PCT application entered the National Phase

  PCT publication WO2005/030182 Priority application(s): WO2005/030182

23 June 2011 Application Accepted

  Published as AU-B-2004275835

20 October 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004275836-Phenyl-piperazine derivatives as modulators of muscarinic receptors

2004275832-Seneca Valley virus based compositions and methods for treating disease